Hengrundasheng's proprietary CD19-targeted CAR-T therapy, Relma-cel Injection, has secured marketing approval for the treatment of adult patients suffering from relapsed or refractory large B-cell lymphoma. This marks the seventh CAR-T therapy to be approved in China, with its efficacy and safety substantiated by Phase II clinical trial results, demonstrating promising outcomes for patients with relapsed or refractory non-Hodgkin's lymphoma. Currently, the pricing for CAR-T therapies in China lies within the range of 999,000 to 1,290,000 yuan. Furthermore, Shanghai Chia Tai Tianqing Pharmaceutical Co., Ltd. has submitted an application for the marketing of Suruca-cel, a CAR-T therapy aimed at treating advanced gastric or gastroesophageal junction adenocarcinoma in solid tumors.